Edward Wilson Grandin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart-Assist Devices | 16 | 2022 | 1288 | 2.900 |
Why?
|
Extracorporeal Membrane Oxygenation | 9 | 2023 | 1462 | 2.360 |
Why?
|
Heart Failure | 22 | 2023 | 11669 | 1.390 |
Why?
|
Ventricular Dysfunction, Right | 7 | 2022 | 628 | 1.260 |
Why?
|
Shock, Cardiogenic | 7 | 2023 | 709 | 0.790 |
Why?
|
Heart Ventricles | 7 | 2022 | 3796 | 0.670 |
Why?
|
Respiratory Insufficiency | 2 | 2023 | 1230 | 0.580 |
Why?
|
Registries | 10 | 2023 | 8207 | 0.550 |
Why?
|
Blood Coagulation | 2 | 2022 | 1154 | 0.550 |
Why?
|
Phosphodiesterase 5 Inhibitors | 3 | 2022 | 103 | 0.510 |
Why?
|
Hemorrhage | 3 | 2022 | 3418 | 0.510 |
Why?
|
Pulsatile Flow | 1 | 2016 | 321 | 0.490 |
Why?
|
Heparin | 1 | 2021 | 1632 | 0.460 |
Why?
|
Drug Substitution | 1 | 2015 | 290 | 0.410 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2022 | 32 | 0.370 |
Why?
|
Thrombosis | 2 | 2021 | 2943 | 0.360 |
Why?
|
Pulmonary Artery | 2 | 2016 | 1927 | 0.360 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2016 | 557 | 0.350 |
Why?
|
Galectin 3 | 1 | 2011 | 240 | 0.340 |
Why?
|
Survival Rate | 4 | 2020 | 12719 | 0.330 |
Why?
|
Anticoagulants | 2 | 2022 | 4785 | 0.330 |
Why?
|
Oligopeptides | 1 | 2014 | 1185 | 0.320 |
Why?
|
Cardiovascular Agents | 1 | 2015 | 839 | 0.320 |
Why?
|
Myocardial Infarction | 4 | 2023 | 11459 | 0.270 |
Why?
|
Drug Prescriptions | 1 | 2015 | 1669 | 0.260 |
Why?
|
Retrospective Studies | 19 | 2023 | 80566 | 0.260 |
Why?
|
Obesity, Morbid | 1 | 2016 | 1276 | 0.250 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 2164 | 0.240 |
Why?
|
Guideline Adherence | 1 | 2015 | 2218 | 0.240 |
Why?
|
Prosthesis Implantation | 2 | 2020 | 591 | 0.240 |
Why?
|
Hospitals | 1 | 2015 | 3877 | 0.200 |
Why?
|
Ventricular Function, Right | 2 | 2022 | 617 | 0.180 |
Why?
|
Hospital Mortality | 4 | 2023 | 5293 | 0.180 |
Why?
|
Factor Xa | 1 | 2021 | 166 | 0.180 |
Why?
|
Intra-Aortic Balloon Pumping | 1 | 2022 | 223 | 0.180 |
Why?
|
Middle Aged | 18 | 2023 | 220584 | 0.170 |
Why?
|
Humans | 33 | 2023 | 760617 | 0.160 |
Why?
|
Acute Coronary Syndrome | 1 | 2011 | 2190 | 0.160 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7389 | 0.150 |
Why?
|
Catheterization | 1 | 2023 | 1428 | 0.150 |
Why?
|
Adult | 16 | 2023 | 220969 | 0.150 |
Why?
|
Multiple Myeloma | 1 | 2014 | 5146 | 0.140 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 568 | 0.140 |
Why?
|
Male | 20 | 2023 | 360358 | 0.130 |
Why?
|
Myocarditis | 1 | 2023 | 788 | 0.130 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2016 | 122 | 0.120 |
Why?
|
Databases, Factual | 3 | 2021 | 7960 | 0.120 |
Why?
|
Female | 20 | 2023 | 392148 | 0.120 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2016 | 273 | 0.120 |
Why?
|
Ventricular Function | 1 | 2016 | 406 | 0.120 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 1040 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 1517 | 0.120 |
Why?
|
Transplants | 1 | 2017 | 206 | 0.120 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12447 | 0.110 |
Why?
|
Hemodynamics | 3 | 2022 | 4160 | 0.110 |
Why?
|
Equipment Failure | 1 | 2016 | 577 | 0.110 |
Why?
|
Vascular Resistance | 1 | 2016 | 930 | 0.110 |
Why?
|
Treatment Outcome | 8 | 2022 | 64568 | 0.110 |
Why?
|
Cardiology | 1 | 2023 | 1656 | 0.100 |
Why?
|
Incidence | 5 | 2021 | 21337 | 0.100 |
Why?
|
Risk Factors | 8 | 2023 | 74115 | 0.090 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 1580 | 0.090 |
Why?
|
Aged | 11 | 2021 | 169042 | 0.080 |
Why?
|
Heptanoic Acids | 1 | 2011 | 344 | 0.080 |
Why?
|
Pravastatin | 1 | 2011 | 392 | 0.080 |
Why?
|
Insurance, Health | 1 | 2021 | 2495 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1998 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39063 | 0.070 |
Why?
|
Medicaid | 1 | 2020 | 2814 | 0.070 |
Why?
|
Stroke Volume | 2 | 2021 | 5486 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2017 | 2118 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6474 | 0.060 |
Why?
|
United States | 5 | 2021 | 72272 | 0.060 |
Why?
|
Pyrroles | 1 | 2011 | 1125 | 0.060 |
Why?
|
Overweight | 1 | 2016 | 2417 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3873 | 0.060 |
Why?
|
Heart Rate | 1 | 2016 | 4180 | 0.060 |
Why?
|
Blood Transfusion | 2 | 2022 | 1299 | 0.060 |
Why?
|
Heart Transplantation | 1 | 2017 | 3232 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12043 | 0.050 |
Why?
|
Medicare | 1 | 2021 | 6765 | 0.050 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 2249 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 3621 | 0.050 |
Why?
|
Comorbidity | 1 | 2016 | 10505 | 0.050 |
Why?
|
Kidney Transplantation | 1 | 2017 | 4236 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5964 | 0.050 |
Why?
|
Cohort Studies | 2 | 2021 | 41457 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 39913 | 0.050 |
Why?
|
Stroke | 1 | 2022 | 9712 | 0.040 |
Why?
|
Hemostasis | 1 | 2022 | 469 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 12943 | 0.040 |
Why?
|
Pilot Projects | 1 | 2011 | 8618 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2021 | 737 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3244 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15498 | 0.030 |
Why?
|
Heart Function Tests | 1 | 2016 | 318 | 0.030 |
Why?
|
Fellowships and Scholarships | 1 | 2023 | 1115 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 10199 | 0.030 |
Why?
|
Obesity | 1 | 2016 | 12933 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1911 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 22148 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3117 | 0.030 |
Why?
|
Prospective Studies | 2 | 2022 | 54360 | 0.030 |
Why?
|
Hospitalization | 2 | 2023 | 10704 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2016 | 58894 | 0.020 |
Why?
|
Prognosis | 1 | 2011 | 29600 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2018 | 2114 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 2017 | 1269 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10073 | 0.020 |
Why?
|
Recovery of Function | 1 | 2018 | 2978 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4237 | 0.020 |
Why?
|
Echocardiography | 1 | 2018 | 4987 | 0.020 |
Why?
|
Quality of Life | 1 | 2023 | 13347 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15251 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20074 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23972 | 0.010 |
Why?
|
Young Adult | 1 | 2017 | 59179 | 0.010 |
Why?
|